BiotechTube

ARS-1 + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Urticaria

Conditions

Urticaria

Trial Timeline

Jul 28, 2022 → Feb 29, 2024

NCT ID
NCT05496465

About ARS-1 + Placebo

ARS-1 + Placebo is a phase 2 stage product being developed by ARS Pharmaceuticals for Urticaria. The current trial status is completed. This product is registered under clinical trial identifier NCT05496465. Target conditions include Urticaria.

What happened to similar drugs?

8 of 20 similar drugs in Urticaria were approved

Approved (8) Terminated (3) Active (10)
✅OMALIZUMABNovartisApproved
✅Levocetirizine + Levocetirizine plus HydroxyzineUCBApproved
✅Levocetirizine + DesloratadineUCBApproved
✅desloratadine + placebo + cetirizineOrganonApproved
✅Desloratadine + Cetirizine + placeboOrganonApproved
✅5-mg Desloratadine + 10-mg Desloratadine + 20-mg DesloratadineOrganonApproved
✅desloratadine + desloratadineOrganonApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05496465Phase 2Completed

Competing Products

20 competing products in Urticaria

See all competitors
ProductCompanyStageHype Score
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
29
THB001Third Harmonic BioPhase 1
11
BriquilimabJasper TherapeuticsPhase 1/2
26
BriquilimabJasper TherapeuticsPhase 1/2
14
BriquilimabJasper TherapeuticsPhase 2
29
CT-P39 + EU-approved XolairCelltrionPhase 3
40
OmalizumabCelltrionPre-clinical
33
LY3454738 + PlaceboEli LillyPhase 2
27
AZD1981 + PlaceboAstraZenecaPhase 2
35
Benralizumab + Placebo and BenralizumabAstraZenecaPhase 2
27
LOU064NovartisPhase 3
40
Ligelizumab + OmalizumabNovartisPhase 3
40
Ligelizumab + PlaceboNovartisPhase 1
21
OmalizumabNovartisPhase 2
35
canakinumabNovartisPhase 2
35
LOU064NovartisPhase 2
35
Omalizumab (Xolair) + PlaceboNovartisPhase 2/3
38
LOU064 Arm 1 + LOU064 Arm 2 + LOU064 Arm 3 + LOU064 Arm 4 + LOU064 Arm 5 + LOU064 Arm 6 + Placebo armNovartisPhase 2
35
LOU064 (blinded) + placeboNovartisPhase 3
47
Remibrutinib + Remibrutinib matching placebo + Dupilumab + Placebo solution for injectionNovartisPhase 3
47